| Literature DB >> 31216870 |
Lutz Heinemann1, Michael Schoemaker2, Günther Schmelzeisen-Redecker2, Rolf Hinzmann2, Adham Kassab3, Guido Freckmann4, Florian Reiterer5, Luigi Del Re5.
Abstract
High-quality performance of medical devices for glucose monitoring is important for a safe and efficient usage of this diagnostic option by patients with diabetes. The mean absolute relative difference (MARD) parameter is used most often to characterize the measurement performance of systems for continuous glucose monitoring (CGM). Calculation of this parameter is relatively easy and comparison of the MARD numbers between different CGM systems appears to be straightforward on the first glance. However, a closer look reveals that a number of complex aspects make interpretation of the MARD numbers provided by the manufacturer for their CGM systems difficult. In this review, these aspects are discussed and considerations are made for a systematic and appropriate evaluation of the MARD in clinical trials. The MARD should not be used as the sole parameter to characterize CGM systems, especially when it comes to nonadjunctive usage of such systems.Entities:
Keywords: blood glucose; continuous glucose monitoring; diabetes therapy; glucose measurement; quality of measurement
Mesh:
Substances:
Year: 2019 PMID: 31216870 PMCID: PMC7189145 DOI: 10.1177/1932296819855670
Source DB: PubMed Journal: J Diabetes Sci Technol ISSN: 1932-2968